营收、净利大幅增长，其中创新药收入超66亿元！一图读懂恒瑞医药2024年半年度报告

文章预览

推荐阅读文章链接： 恒瑞医药子公司AAV双基因药物国内IND获受理 注释： 1.Caicun Zhou, et al. 2024 ELCC Abstract 61.   2.Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised,multicentre, open-label, phase 3 trial. Lancet Oncol 2022; 23: 77–90. 3.Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382: 1894–905. 4.Kelley RK, Rimassa L, Cheng A-L, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised,phase 3 trial. Lancet Oncol 2022; 23: 995–1008. 5.Llovet JM, Kudo M, Merle P, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Lancet Oncol. 2023 Dec;24(12):1399-1410. 6.Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevaci ………………………………